NASDAQ · Healthcare · Biotechnology
Regeneron Pharmaceuticals, Inc. (REGN)
As of Sep 25, 4:00 PM ET, Regeneron Pharmaceuticals (REGN) last traded at $788.04, down 1.00% on the day. Its TickerHum research score is 71/100 (above average). It reported revenue of $15.53B for the twelve months ending 2026-06-30, up 9.3% year over year, with a 24.7% operating margin.
Ratings
- Valuation: 77/100 — Strongest input: price / earnings (ttm) 19.5x. Weakest: free-cash-flow yield 5.1 %.
- Growth: 42/100 — Strongest input: revenue growth (ttm, yoy) +9.3 %. Weakest: diluted eps growth (ttm, yoy) +1.8 %.
- Profitability: 75/100 — Strongest input: net margin 27.9 %. Weakest: return on equity 13.7 %.
- Financial health: 93/100 — Strongest input: current ratio 3.34. Weakest: cash / long-term debt 1.24.
- Momentum: 74/100 — Strongest input: 3-month return +24.5 %. Weakest: 6-month return +4.1 %.
- Attention: 56/100 — Strongest input: headlines in the last 7 days 16. Weakest: volume vs 3-month average 0.8x.
- Risk: 67/100 — Strongest input: annualised volatility (1y) 32.9 %. Weakest: max drawdown (1y) -26.1 %.
- Data confidence: 90/100 — Strongest input: latest financial period age (days) 90 d. Weakest: quote age (hours) 45 h.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $15.53B | TTM ending 2026-06-30 · 10-Q |
| Revenue growth | 9.3% | TTM ending 2026-06-30 · 10-Q |
| Net income | $4.33B | TTM ending 2026-06-30 · 10-Q |
| Diluted EPS | $40.41 | TTM ending 2026-06-30 · 10-Q |
| Operating margin | 24.7% | TTM ending 2026-06-30 · 10-Q |
| Net margin | 27.9% | TTM ending 2026-06-30 · 10-Q |
| Free cash flow | $3.76B | TTM ending 2026-06-30 · 10-Q |
| Cash | $2.46B | as of 2026-06-30 · 10-Q |
| Long-term debt | $1.99B | as of 2026-06-30 · 10-Q |
| Debt / equity | 0.06 | as of 2026-06-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000872589).
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.